• 1. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 2. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 3. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 4. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 5. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl-phenylketones

Introduction to (S)-2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic Acid (CAS No. 606-14-4)

(S)-2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid, identified by its CAS number 606-14-4, is a compound of significant interest in the field of chemical and biomedical research. This molecule, featuring a chiral center, has garnered attention due to its structural complexity and potential biological activities. The presence of both amino and hydroxyl functional groups, along with its oxobutanoic acid moiety, makes it a versatile scaffold for the development of various pharmacological agents.

The compound’s stereochemistry, specifically the (S) configuration at the chiral center, plays a crucial role in determining its biological efficacy. Chiral drugs often exhibit different pharmacological profiles depending on their stereochemical orientation, making the precise synthesis and characterization of such compounds essential for therapeutic applications. Recent advancements in asymmetric synthesis have enabled the production of enantiomerically pure forms of this compound, which is critical for ensuring the safety and efficacy of derivative drugs.

In the realm of drug discovery, (S)-2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid has been explored as a precursor for novel therapeutic agents. Its structural features suggest potential applications in the treatment of inflammatory diseases, metabolic disorders, and even certain types of cancer. The hydroxyl group, in particular, can serve as a site for further functionalization, allowing chemists to design molecules with tailored biological activities.

Recent studies have highlighted the compound’s role in modulating enzyme activity. For instance, derivatives of this molecule have been shown to inhibit specific kinases involved in cellular signaling pathways. These pathways are often dysregulated in diseases such as cancer and autoimmune disorders, making such inhibitors promising candidates for therapeutic intervention. The oxobutanoic acid moiety also contributes to the compound’s reactivity, enabling it to participate in various biochemical transformations that could be exploited for drug development.

The synthesis of (S)-2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid presents both challenges and opportunities. Traditional synthetic routes often require multiple steps and harsh conditions, which can lead to low yields and the formation of byproducts. However, recent innovations in green chemistry have led to more sustainable methods for producing this compound. These methods leverage catalytic systems that minimize waste and energy consumption while maintaining high selectivity and yield.

Another area of interest is the use of computational modeling to predict the biological activity of this compound. Advanced computational techniques can simulate how the molecule interacts with biological targets such as enzymes and receptors. This approach not only accelerates the drug discovery process but also helps in understanding the molecular basis of its pharmacological effects. Such insights are invaluable for designing next-generation drugs with improved efficacy and reduced side effects.

The pharmaceutical industry has shown significant interest in developing derivatives of (S)-2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid for clinical use. Preclinical studies have demonstrated its potential as an anti-inflammatory agent, with promising results in animal models of arthritis and other inflammatory conditions. Additionally, its ability to modulate metabolic pathways makes it a candidate for treating metabolic syndrome and related disorders.

In conclusion, (S)-2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid (CAS No. 606-14-4) is a multifaceted compound with significant potential in biomedical research and drug development. Its unique structural features and stereochemistry make it an attractive scaffold for designing novel therapeutic agents. With ongoing advancements in synthetic chemistry and computational biology, the future looks promising for harnessing this compound’s full potential in addressing various human diseases.

• 2147-61-7(2-Amino-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid)
• 484-78-6(Benzenebutanoic acid, a,2-diamino-3-hydroxy-g-oxo-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)